Amplia has announced that a fourth patient enrolled in the Company’s Phase 2a clinical trial investigating narmafotinib in the treatment of advanced pancreatic cancer has recorded a confirmed partial response.
A confirmed partial response’ means in these patients there is at least a 30% decrease in the overall size of tumour lesions, with no new tumour lesions, sustained over a two-month period. The ACCENT trial protocol requires that six (6) of the 26 patients enrolled in the first cohort achieve this response level for the trial to continue with enrolment of an additional 24 patients.
Amplia CEO and MD Dr Chris Burns commented:
“The activity of narmafotinib in the ACCENT trial continues to be very positive, consistent with our previous clinical and preclinical data. We remain on track to complete the interim analysis by the end of this quarter.”
Click here to read the ASX release.
